Schizophrenia Research
Volume 122, Issue 1 , Pages 1-23 , September 2010

Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future

Received 5 March 2010 ,Revised 22 May 2010 ,Accepted 25 May 2010.

References 

  1. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry. 2001;179:290–299
  2. Adams CE, Coutinho E, Davis JM, et al. Cochrane Schizophrenia Group publications. The Cochrane Library. Chichester, United Kingdom: John Wiley and Sons Ltd.; 2009;Accessed at szg.cochrane.org
  3. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry. 2003;60:1228–1235
  4. Aleman A, Somner IE, Kahn RS. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J. Clin. Psychiatry. 2007;68:416–421
  5. Alkhateeb H, Essali A, Matar HED, et al. Cessation of medication for people with schizophrenia already on chlorpromazine. Cochrane Database Systematic Reviews CD006329. 2007;
  6. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  7. Aloyo VJ, Berg KA, Spampinato U, et al. Current status of inverse agonism at serotonin 2A and 2C receptors. Pharmacol. Ther. 2009;121:160–173
  8. Alvarez-Jimenez, M., Parker, A.G., Hetrick, S.E., et al., in press. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr. Bull. doi:10.1093/schbul//sbp129
  9. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry. 2010;67:146–154
  10. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry. 2005;162:441–449
  11. Armenteros JL, Davies M. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur. Child Adolesc. Psychiatry. 2006;15:141–148
  12. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol. 1998;18:63–101
  13. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr. Bull. 2008;34:1130–1144
  14. Baloyianni N, Tsangaris GT. The audacity of proteomics: a challenge to overcome current challenges in schizophrenia research. Expert Rev. Proteomics. 2009;6:661–674
  15. Barch DM, Carter CS, Arnstein A, et al. Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr. Bull. 2009;35:109–114
  16. Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. Schizophr. Res. 2004;70:33–37
  17. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet. 2002;11:2517–2530
  18. Benton MK, Schroeder HE. Social skills training with schizophrenia: a meta-analytic evaluation. J. Consult. Clin. Psychol. 1990;58:741–747
  19. Bilder R. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can. J. Psychiatry. 1997;42:326–330
  20. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry. 1998;172:53–59suppl
  21. Blanc O, Brousse G, Meary A, Daskalakis ZJ. Pharmacogenetics of response efficacy of antipsychotics in schizophrenia. Fundam. Clin. Pharmacol. 2010;24:139–160
  22. Blumberger DM, Fitzgerald PB, Mulsant BH, Daskalakis ZJ. Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia. Curr. Opin. Psychiatry. 2010;23:85–90
  23. Bollini P, Pampallona S, Nieddu S, et al. Indicators of conformance with guidelines of schizophrenia treatment in mental health services. Psychiatr. Serv. 2008;59:782–791
  24. Bond GR. Assertive outreach for frequent users of psychiatric hospitals: a meta-analysis. J. Ment. Health Adm. 1995;22:4–16
  25. Bonham C, Abbott C. Are second-generation antipsychotics a distinct class?. J. Psychiatr. Pract. 2008;14:225–237
  26. Bortolato M, Frau R, Orru M, et al. Antipsychotic properties of 5-alpha-reductase inhibitors. Neuropsychopharmacol. 2008;33:3146–3156
  27. Bosanac P, Patton GC, Castle DJ. Early intervention in psychotic disorders: faith before facts?. Psychol. Med. 2010;40:353–358
  28. Bradley SR, Lameh J, Ohrmund L, et al. AC-260584, an orally bioavailable M(1) receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology. 2010;58:365–373
  29. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J. ECT. 2005;21:75–83
  30. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch. Gen. Psychiatry. 1991;48:239–246
  31. Brennan JA, Graf R, Grauer SM, et al. WS-50030: a novel dopamine D-2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J. Pharmacol. Exp. Ther. 2010;32:190–201
  32. Brown GW, Birley JL, Wing JK. Influence of family life on the course of schizophrenic illness: a replication. Br. J. Psychiatry. 1972;121:241–258
  33. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010;36:71–93
  34. Burns T, Catty J, Dash M, et al. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ. 2007;335:336–340
  35. Bustillo JR, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am. J. Psychiatry. 2001;158:163–175
  36. Campbell K, Bond GR, Drake RE. Who benefits from supported employment: A meta-analytic study. Schizophr. Bull. 2009;doi:10.1093/schbul//sbp066.2009
  37. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacol. 2008;33:2061–2079
  38. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 1988;145:578–583
  39. Casey JE, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic patients with phenothiazine derivatives. Am. J. Psychiatry. 1960;116:97–105
  40. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001;158:518–526
  41. Chanpattana W, Kramer BA, Kunigiri G, et al. A survey of the practice of electroconvulsive therapy in Asia. J. ECT. 2010;26:5–10
  42. Charych EI, Liu F, Moss SJ, Brandon NJ. GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacol. 2009;57:481–495
  43. Chen H, Tandon R. First- and second-generation antipsychotics and the concept of “atypicality”: implications for clinical practice. Psychopharmacol. Rev. 2009;44:81–88
  44. Chien W-T, Chan SWC, Thompson DR. Effects of a mutual support group for families of Chinese people with schizophrenia. Br. J. Psychiatry. 2006;189:41–49
  45. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J. Clin. Psychiatry. 2009;70:122–129
  46. Coldwell CM, Bender WS. The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am. J. Psychiatry. 2007;164:393–399
  47. Cole JO. Evaluation of drug treatments in psychiatry. Proc. Annu. Meet. Am. Psychopathol. Assoc. 1964;52:14–31
  48. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chron. Dis. 2006;3:11–14
  49. Compton MT. Considering schizophrenia from a prevention perspective. Am. J. Prev. Med. 2004;26:178–185
  50. Conn JP, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009;30:25–31
  51. Cornblatt BA, Lencz T, Smith CW, et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry. 2007;68:546–557
  52. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. Br. Med. J. 2001;322:1207–1209
  53. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–483
  54. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist. Psychiatry. 2007;18:39–60
  55. Crossley NA, Constante M, NcGuire P, Power P. Efficacy of atypical V. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br. J. Psychiatry. 2010;196:434–439
  56. Davidson L, Drake RE, Scmutte T, et al. Oil and water or oil and vinegar? Evidence-based medicine meets vinegar. Community Ment. Health J. 2009;45:323–332
  57. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry. 2009;166:675–682
  58. Davis JM, Gosenfeld L, Tsai CC. Maintenance antipsychotic drugs do prevent relapse. Psychol. Bull. 1976;83:431–447
  59. Davis JM, Schaffer CB, Killam GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr. Bull. 1980;6:70–87
  60. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 2003;60:553–564
  61. Dawson LA, Smith PW. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr. Pharm. Des. 2010;16:344–357
  62. De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness. Eur. Psychiatry. 2009;24:412–424
  63. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr. Res. 2010;117:68–74
  64. De Koning MB, Bloemen OJN, van Amelsvoort TAMJ, et al. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr. Scand. 2009;119:426–442
  65. De Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol. Res. 2009;59:81–89
  66. De Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 2005;46:262–273
  67. Delay J, Deniker P, Harl J. Traitement des etats d'excitation et d'agitation par une methode medicamenteuse derive de l'hibernotherapie. Ann. Medicopsychol. 1952;119:267–273
  68. Derks EM, Fleischhacker WW, Boter H, et al. Antipsychotic drug treatment in first-episode psychosis. J. Clin. Psychopharmacol. 2010;30:176–180
  69. Deutch SI, Rosse RB, Mastropaolo J, et al. Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time ?. Clin. Neuropharmacol. 2008;31:104–119
  70. DeQuardo JR, Tandon R. Do atypical antipsychotics favorably alter the long-term course of schizophrenia. J. Psychiatr. Res. 1998;32:229–242
  71. Dickinson D, Tenhula W, Morris S, et al. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am. J. Psychiatry. 2010;167:170–180
  72. Dixon LB, Dickerson F, Bellack AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr. Bull. 2010;36:48–70
  73. Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative and cognitive symptoms of schizophrenia: review and meta-analysis. J. Clin. Psychiatry. 2010;71:411–418
  74. Drake RE, Bond GR, Essock SM. Implementing evidence-based practices for people with schizophrenia. Schizophr. Bull. 2009;35:704–713
  75. Durham RC, Chambers JA, Power KG, et al. Long-term outcome of cognitive behavior therapy clinical trials in central Scotland. Health Technol. Assess. 2005;9(42):1–174
  76. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 2007;33:1225–1237
  77. Eack SM, Hogarty GE, Cho RY, et al. Neuroprotective effects of cognitive enhancement therapy in schizophrenia. Arch. Gen. Psychiatry. 2010;67(7):doi:10.1001/archgenpsychiatry2010.63
  78. Eisch AJ, Cameron HA, Encinas JM, et al. Adult neurogenesis, mental health, and mental illness: hope or hype?. J. Neurosci. 2008;28:11785–11791
  79. Elmer GI, Kafkaki N. Drug discovery in psychiatric illness: mining for gold. Schizophr. Bull. 2009;35:287–292
  80. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry. 2006;163:743–745
  81. Falkai P, Wobrock T, Lieberman JA, et al. World Federation of Societies of Biological Psychiatry guidelines for biological treatment of schizophrenia, part 1: acute treatment. World J. Biol. Psychiatry. 2005;6:132–191
  82. Fatemi SH. Potential microbial origins of schizophrenia and their treatments. Drugs Today. 2009;45:305–318
  83. Fischer-Barnicol D, Lanquillon S, Haen E, et al. Typical and atypical antipsychotics — the misleading dichotomy. Neuropsychobiology. 2008;57:80–87
  84. Fisher M, Holland C, Merzenich MM, Vivogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry. 2009;166:805–811
  85. Folsom DP, Hawthorne W, Lindamer L, et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10, 340 patients with severe mental illness in a large public mental health system. Am. J. Psychiatry. 2005;162:370–376
  86. Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 2009;108:11–14
  87. Freyberg Z, Ferrando SJ, Javitch JA. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am. J. Psychiatry. 2010;167:388–396
  88. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr. Res. 2007;95:19–29
  89. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am. J. Psychiatry. 2010;167:686–693
  90. Gardos G, Cole O. The importance of dosage in antipsychotic drug administration: a review of dose–response studies. Psychopharmacology. 1973;29:221–230
  91. Garety P, Fowler DG, Freeman D, et al. Cognitive–behavioral therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomized controlled trial. Br. J. Psychiatry. 2008;192:412–423
  92. Garver DL. Evolution of antipsychotic intervention in schizophrenia. Curr. Drug Targets. 2006;7:1205–1215
  93. Gaspar PA, Bustamante L, Silva H, Aboitiz F. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J. Neurochem. 2009;111:891–900
  94. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: >>systematic overview and meta-regression analysis. BMJ. 2000;231:1371–1376
  95. Geffen Y, Nudelman A, Gil-Ad I, et al. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur. Neuropsychopharmacol. 2009;19:1–13
  96. Gerretsen P, Muller DJ, Tiwari A, et al. The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. Dialogues Clin. Neurosci. 2009;11:363–376
  97. Gilbert P, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch. Gen. Psychiatry. 1995;52:173–188
  98. Giron M, Fernandez-Yanez A, Mana-Alvarenga S, et al. Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study. Psychol. Med. 2010;40:73–84
  99. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death. Am. J. Psychiatry. 2001;158:1774–1782
  100. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry. 2007;64:1115–1122
  101. Gould RA, Mueser KT, Bolton E, et al. Cognitive therapy for schizophrenia: an effect size analysis. Schizophr. Res. 2001;48:335–342
  102. Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a model for the therapeutic action of antipsychotic drugs. Trends Neurosci. 1997;20:31–37
  103. Grauer SM, Pulito VL, Navarra RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative, symptoms of schizophrenia. J. Pharmacol. Exp. Ther. 2009;331:574–590
  104. Grayson DR, Kundakovic M, Sharma RP. Is there a role for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol. Pharmacol. 2010;77:126–135
  105. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  106. Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol. Psychiatry. 2001;49:374–384
  107. Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia, and mania: systematic reviews and economic modeling studies. Health Technol. Assess. 2005;9:1–156
  108. Grunder G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009;8:197–202
  109. Haase H-J, Janssen PAJ. The Action of Neuroleptic Drugs. Amsterdam, Holland: North Holland Publishing Company; 1965;
  110. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs. 2004;64:2291–2314
  111. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol. Rev. 2009;19:324–335
  112. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 2009;35:300–306
  113. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry. 2001;158:176–184
  114. Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors — targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr. Top. Med. Chem. 2010;10:144–152
  115. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev. Neurother. 2010;10:43–57
  116. Hogarty GE, Anderson C, Reiss D, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. Arch. Gen. Psychiatry. 1986;43:633–642
  117. Hogarty GE, Kornblith SJ, Greenwald D. Three year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. Am. J. Psychiatry. 1997;154:1504–1513
  118. Hollister LE. Clinical differences among phenothiazines in schizophrenics. In:  Forrest IS,  Carr CJ,  Usdin E editor. The Phenothiazines and Structurally Related Drugs. New York: Raven Press; 1974;p. 667–673
  119. Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry. 2006;67:897–903
  120. Hughes B. Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat. Rev. Drug Discov. 2009;8:523–524
  121. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research in mental illness. Arch. Gen. Psychiatry. 2009;66:128–133
  122. Jackson MJ, Andree TH, Hansard M, et al. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. J. Neural Transm. 2010;117:55–67
  123. Jager M, Riedel M, Obermeier M, et al. Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients. Schizophr. Res. 2010;118:183–188
  124. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opin.Drug Discov. Develop. 2009;12:468–478
  125. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31
  126. Johnstone EC, Crow TJ, Frith CD, et al. Mechanism of antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978;1(8069):848–851
  127. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry. 2006;63:1079–1087
  128. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008;371:1085–1097
  129. Kane JM. Tardive dyskinesia circa 2006. Am. J. Psychiatry. 2006;163:1316–1318
  130. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  131. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacological treatment of psychotic disorders. Introduction, methods, commentary, and summary. J. Clin. Psychiatry. 2003;64(Suppl. 12):5–19
  132. Kanuma K, Aomi T, Shimazaki Y. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. Recent Pat. CNS Drug Discov. 2010;5:23–34
  133. Kapur S, Remington G. Dopamine D2 receptors and their role in antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry. 2001;50:873–883
  134. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side-effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 2000;157:514–520
  135. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis-linking biology, pharmacology, and pharmacology of psychosis. Schizophr. Res. 2005;79:59–68
  136. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry. 2007;64:633–647
  137. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr. Bull. 2009;35:347–361
  138. Keshavan MS, Tandon R, Boutros N, Nasrallah HA. Schizophrenia, “Just the Facts”. What we know in 2008. Part 3: pathophysiology. Schizophr. Res. 2008;106:89–107
  139. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6:78–85
  140. Kingdon D. Over-simplification and exclusion of non-conforming studies can demonstrate absence of effect: a lynching party. Psychol. Med. 2010;40:25–27
  141. Kinon BJ, Ahl J, Stauffer VL, et al. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs. 2004;18:597–616
  142. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacol. 2010;35:581–590
  143. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006;32:214–219
  144. Kiss B, Horvath A, Nemethy ZS, et al. Cariprazine (RGH-188), a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 2010;333:328–340
  145. Kooyman I, Dean K, Harvey S, Walsh E. Outcomes of public concern in schizophrenia. Br. J. Psychiatry. 2007;191:s29–s36Supplement
  146. Kozikowski AP, Cho SJ, Jensen NJ, et al. HTS and rational drug design to generate a new class of 5-HT2C-selective ligands for possible use in schizophrenia.. Chem. Med. Chem. 2010;5:1221–1225
  147. Krabbendam L, Aleman A. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol. Med. 2003;33:756–758
  148. Kraepelin E. Dementia Praecox and Paraphrenia, 1919, edited by Robertson GM), Krieger, New York, 1971.
  149. Krystal JH, Tolin DF, Sanacora G, et al. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov. Today. 2009;14:690–697
  150. Kurtz MM, Mueser KT. A meta-analysis of controlled research on social skills training for schizophrenia. J. Consult. Clin. Psychol. 2008;76:491–504
  151. Labrie V, Roder JC. The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 2010;34:351–372
  152. Lambert M, Schimmelmann BG, Naber D, et al. Early- and delayed-antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2010;42:277–283
  153. Leach K, Loiacono RE, Felder CC, et al. Molecular mechanism of action and in vivo validation of an M4 muscarinic receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacol. 2010;35:855–869
  154. Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental illness and substance use disorders: a clinical trial. J. Nerv. Ment. Dis. 1993;181:86–90
  155. Lehman AF, Goldberg R, Dixon LB, et al. Improving employment outcomes for persons with severe mental illnesses. Arch. Gen. Psychiatry. 2002;59:165–172
  156. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia. Am. J. Psychiatry. 2004;161:1–56
  157. Lesage A, Steckler T. Metabotropic glutamate mGlu1 receptor stimulation and blockade: Therapeutic opportunities in psychiatric illness. Eur. J. Pharmacology. 2010;639:2–16
  158. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 1999;35:51–68
  159. Leucht S, McGrath J, White P, Kissling W. Carbamazepine augmentation for schizophrenia: how good is the evidence?. J. Clin. Psychiatry. 2002;63:218–224
  160. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics. A systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry. 2003;160:1209–1222
  161. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry. 2004;65:177–186
  162. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry. 2005;57:1543–1549
  163. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry. 2009;14:429–447
  164. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41
  165. Leucht S, Komossa K, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry. 2009;166:152–163
  166. Levander S, Eberhard J, Lindstrom E. Clinical decision-making during 5years of antipsychotic treatment. Acta Psychiatr. Scand. 2007;116(Suppl. 435):17–26
  167. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr. Bull. 2010;36:624–632
  168. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry. 2010;71:138–149
  169. Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol. Rev. 2008;33:141–165
  170. Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies. J. Clin. Investig. 2009;119:706–716
  171. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006;32:715–723
  172. Lieberman JA, Dody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry. 1993;50:369–376
  173. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J. Med. 2005;353:1209–1233
  174. Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J. Clin. Psychiatry. 2006;67:983–990
  175. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacol. 2009;34:1322–1329
  176. Lincoln TM, Wilhelm K, Nestoriuc . Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence, and functioning in psychotic disorders: a meta-analysis. Schizophr. Res. 2007;96:232–245
  177. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst. Rev. CD007778.. 2009;
  178. Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry. 1992;149:1183–1188
  179. Lynch D, Laws KR, McKenna PJ. Cognitive behavior therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol. Med. 2010;40:9–24
  180. Malmberg L, Fenton M, Rathbone J. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews CD001360. 2009;
  181. Marder SR, Fenton WS. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res. 2004;72:5–9
  182. Marder SR, Essock SM, Miller AM, et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry. 2004;161:1334–1349
  183. Mari JDJ, Streiner DL. An overview of family intervention and relapse on schizophrenia: meta-analysis of research findings. Psychol. Med. 1994;24:565–578
  184. Marino MJ, Knutsen LJS, Williams M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J. Med. Chem. 2008;51:1077–1107
  185. Markou A, Chiamulera C, Geyer MA. Removing obstacles in neuroscience drug discovery: the future path of animal models. Neuropsychopharmacol. 2009;34:74–89
  186. Marshall M, Lockwood A. Assertive community treatment for persons with severe mental disorders. Cochrane Database of Systematic Reviews CD001089. 1998;
  187. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database of Systematic Reviews CD004718. 2006;
  188. Marwaha S, Johnson S. Schizophrenia and employment — a review. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39:337–349
  189. Matheson SL, Green MJ, Loo C, Carr VJ. Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial stimulation for schizophrenia: A systematic meta-review. Schizophr. Res. 2010;118:201–210
  190. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of typical antipsychotics. Clin. Pharmacokinet. 2007;46:359–388
  191. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Res. 1992;41:147–154
  192. McCreary AC, Jones CA. Antipsychotic medication: the potential role of 5HT1A receptor agonism. Curr. Pharm. Des. 2010;16:516–521
  193. McEvoy JP, Lieberman JA, Stroup JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am. J. Psychiatry. 2006;163:600–610
  194. McFarlane WR, Lukens F, Link B, et al. Multiple family groups and psychoeducation in the treatment of schizophrenia. Arch. Gen. Psychiatry. 1995;52:679–687
  195. McGlashan TH, Zipursky RB, Perkins D, et al. Randomized double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry. 2006;163:790–799
  196. McGorry PD, Yung AR, Phillips LJ. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59:921–928
  197. McGorry PD, Nelson B, Amminger P, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J. Clin. Psychiatry. 2009;70:1206–1212
  198. McGrath J. Is it time to trial vitamin D supplements for the prevention of schizophrenia?. Acta Psychiatr. Scand. 2010;121:321–324
  199. McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry. 2007;164:1791–1802
  200. Medalia A, Choi J. Cognitive remediation in schizophrenia. Neuropsychol. Rev. 2009;19:353–364
  201. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 1989;251:238–246
  202. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 2003;60:82–91
  203. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacol. 2010;35:881–892
  204. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  205. Meyer JM, Loebel AD, Schweizer E, et al. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs. 2009;18:1715–1726
  206. Mikell CB, McKhann GM, Segal S, et al. The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. Stereotact. Funct. Neurosurg. 2009;87:256–265
  207. Mikkelsen JD, Thomsen MS, Hansen HH, Lichota J. Use of biomarkers in the discovery of novel antischizophrenia drugs. Drug Discovery Today. 2010;15:137–141
  208. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psychiatry. 2004;55:1013–1022
  209. Mistler LA, Drake RE. Shared decision-making in antipsychotic management. J. Psychiatr. Pract. 2008;14:333–344
  210. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry. 2005;10:79–104
  211. Mojtabai R, Malaspina D, Susser E. The concept of population prevention: application to schizophrenia. Schizophr. Bull. 2003;29:791–801
  212. Mojtabai R, Fochtmann L, Chang SW, et al. Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. Schizophr. Bull. 2009;35:679–695
  213. Money TT, Scarr E, Udawela M, et al. Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol. Disord. Drug Targets. 2010;9:241–256
  214. Morrison AP, French P, Walford L, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br. J. Psychiatry. 2004;185:291–297
  215. Mortimer AM. Cognitive function in schizophrenia — do neuroleptics make a difference?. Pharmacol. Biochem. Behav. 1997;56:789–795
  216. Mrazek PJ, Haggerty RJ. Reducing risks for mental disorders: frontiers for preventive intervention research. Washington, D.C: National Academy Press; 1994;
  217. Muller N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs. 2010;11:31–42
  218. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 2007;115:260–267
  219. Nasrallah HA, Tandon R. Classic antipsychotic medications. In:  Nemeroff C,  Schatzberg A editor. American Psychiatric Press Textbook of Psychopharmacology. 4th edition. American Psychiatric Press: Washington D.C; 2009;p. 533–554
  220. Nasrallah HA, Targum SD, Tandon R, et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 2005;56:273–282
  221. National Research Council and Institute of Medicine . Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. Washington, D.C: National Acadamies Press; 2009;
  222. Nelson G, Aubry T, Lafrance A. A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am. J. Orthopsychiatry. 2007;77:350–361
  223. Neves G, Menegatti R, Antonio CB, et al. Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D@-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry. 2010;18:1925–1935
  224. Newcomer J, Haupt D. The metabolic effects of antipsychotic medications. Can. J. Psychiatry. 2006;51:480–491
  225. NICE . Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). London: National Institute of Clinical Excellence; 2009;
  226. Ozbilen M, Adams CE. Systematic review of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J. Clin. Psychopharmacol. 2009;29:141–146
  227. Painuly N, Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. J. ECT. 2006;22:59–66
  228. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 2007;13:1102–1107
  229. Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr. Res. 2008;100:108–119
  230. Penn DL, Waldheter EJ, et al. Psychosocial treatment for first-episode psychosis: a research update. Am. J. Psychiatry. 2005;162:2220–2232
  231. Perkins DO, Hongbin G, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry. 2005;162:1785–1804
  232. Pfammatter M, Junghan UM, et al. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr. Bull. 2006;32(Suppl 1):S64–S80
  233. Pharaoh F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database of Systematic Reviews CD000088. 2006;
  234. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behavior therapy. Psychol. Med. 2002;32:763–782
  235. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: II. Meta-analysis of randomized controlled trials of social skills training and cognitive remediation. Psychol. Med. 2002;32:783–791
  236. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr. Bull. 2001;27:73–92
  237. Porsolt RD, Moser PC, Castagne V. Behavioral indices in antipsychotic drug discovery.. J. Pharmacol. Exp. Ther. 2010;333:632–638
  238. Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry. 2007;12:232–246
  239. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Eng. J. Med. 2009;360:225–235
  240. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. J. Nerv. Ment. Dis. 2001;189:278–287
  241. Remington G, Foussias G, Agid O. Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs. 2010;24:9–20
  242. Ren M-S, Chan CL-W, Chen EY-H, et al. Differences in mortality and suicidal behavior between treated and never-treated people with schizophrenia in rural China. Br. J. Psychiatry. 2009;195:126–131
  243. Reynolds GP. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov. Today. 2007;12:953–959
  244. Ritsner MS. Pregnelenone, dehydroepiandrosterone, and schizophrenia: Alterations and clinical trials. CNS Neuroscience and Therapeutics. 2010;16:32–44
  245. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999;156:54–549
  246. Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis. Expert Rev. Neurother. 2009;9:47–54
  247. Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central canabinoid (CB1) receptor antagonists. World J. Biol. Psychiatry. 2010;11:208–219
  248. Rosse G, Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr. Top. Med. Chem. 2010;10:207–221
  249. Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating working memory and mood interact with the synonymous catechol-O-methyltransferase rs4818 c/g polymorphism. Biol. Psychiatry. 2009;66:997–1004
  250. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Intervention in the at-risk state to prevent transition to psychosis. Curr. Opin. Psychiatry. 2009;22:177–183
  251. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time. Arch. Gen. Psychiatry. 2007;64:1123–1131
  252. Sakel M. New treatment for schizophrenia. Am. J. Psychiatry. 1937;93:829–841
  253. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009;23:837–855
  254. Salokangas RKR, McGlashan TH. Early detection and intervention of psychosis: a review. Nord. J. Psychiatry. 2008;62:92–105
  255. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 2008;325:681–690
  256. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717–719
  257. Sherwood M, Thornton AE, Honer WG. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. Int. J. Neuropsychopharmacol. 2006;9:357–366
  258. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry. 2008;165:1420–1431
  259. Sluciak JA. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs. 2008;22:983–993
  260. Smith M, Hopkins D, Peveler RC, et al. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. 2008;
  261. Srisurapanont M, Maneeton N. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials. J. Med. Assoc. Thai. 1999;82:341–346
  262. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr. Scand. 2007;115:4–11
  263. Stahl SM, Mignon L, Meyer JM. What comes first: atypical antipsychotics or the metabolic syndrome?. Acta Psychiatr. Scand. 2008;119:171–179
  264. Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am. J. Med. 2007;120:S26–S31
  265. Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry. 2004;37(Suppl. 1):S70–S78
  266. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry. 2007;164:428–436
  267. Swayze VWI. Frontal leucotomy and related psychosurgical procedures in the era before antipsychotics (1935–1954): a historical review. Am. J. Psychiatry. 1995;152:505–515
  268. Tai S, Turkington D. The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. Schizophr. Bull. 2009;35:865–873
  269. Takano A. The application of PET technique for the development and evaluation of novel antipsychotics. Curr. Pharm. Des. 2010;16:371–377
  270. Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The author's reply. Arch. Gen. Psychiatry. 2006;63:935–939
  271. Tandon R, Ribeiro SCM, DeQuardo JR, et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol. Psychiatry. 1993;34:495–497
  272. Tandon R, Goldman R, DeQuardo JR, et al. Covariance of positive and negative symptoms during clozapine treatment in schizophrenia. J. Psychiatr. Res. 1993;27:341–347
  273. Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 2006;12:348–363
  274. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “Just the Facts”. What we know in 2008. Part 1: overview. Schizophr. Res. 2008;100:4–19
  275. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, “Just the Facts”. What we know in 2008. Part 2: epidemiology and etiology. Schizophr. Res. 2008;102:1–18
  276. Tandon R, Moller H-J, Belmaker RH, et al. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008;100:20–38
  277. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “Just the Facts” 4. Clinical features and conceptualization. Schizophr. Res. 2009;110:1–23
  278. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale?. Behav. Res. Ther. 2004;42:1377–1401
  279. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin. Ther. Targets. 2007;11:1189–1206
  280. Tharyan P, Adams CE, Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst. Rev. CD000076. 2005;
  281. Thirthalli J, Venkatesh BK, Kishorekumar KV, et al. Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients. Acta Psychiatr. Scand. 2008;119:209–217
  282. Thirthalli J, Phutane VH, Muralidharan K, et al. Does catatonic schizophrenia improve faster with electroconvulsive therapy than other subtypes of schizophrenia ?. World J. Biol. Psychiatry. 2009;10:772–777
  283. Thirthalli J, Venkatesh BK, Naveen MN. Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community. Indian J. Psychiatry. 2010;52:37–41
  284. Thomas P, Alptekin K, Gheorghe M, et al. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs. 2009;23:193–212
  285. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nation-wide cohort of 2230 patients in community care after the first hospitalization due to schizophrenia and schizoaffective disorder. BMJ. 2006;333:2224–2227
  286. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620–627
  287. Tiihonen J, Wahlbeck K, et al. “The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2009;109:10–14
  288. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin. Investig. Drugs. 2009;18:1519–1531
  289. Tungpunkom P, Nicol M. Life skills programmes for chronic mental illnesses. Cochrane Database of Systematic Reviews, CD000381. 2008;
  290. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Focus. 2008;6:257–266
  291. Twamley EW, Jeste DV, et al. A review of cognitive training in schizophrenia. Schizophr. Bull. 2003;29:359–382
  292. Tyrer P, Kendall T. The spurious advance of antipsychotic therapy. Lancet. 2009;362:404–405
  293. Velligan DI, Kern RS, Gold JM. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr. Bull. 2006;32:474–485
  294. Verhoest PR, Chapin DS, Corman M, et al. Discovery of a new class of phosphodiesterase 10A inhibitors and identification of clinical candidate for the treatment of schizophrenia. J. Med. Chem. 2009;52:5188–5196
  295. Volpi S, Potkin SG, Malhotra AK. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry. 2009;70:801–809
  296. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst. Rev. CD006391. 2007;
  297. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology. 2004;171:121–132
  298. Waghorn G, Chant D, White P, Whitehead H. Delineating disability, labour force participation and employment restrictions among persons with psychosis. Acta Psychiatr. Scand. 2004;109:279–288
  299. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry. 1999;156:990–999
  300. Waraich PS, Adams CE, Roque M, et al. Haloperidol dose in the acute phase of schizophrenia. Cochrane Database Systematic Reviews CD001951. 2002;
  301. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J. Psychiatr. Pract. 2007;13:13–24
  302. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009;113:1–11
  303. Whitehead C, Moss S, Cardno A, et al. Antidepressants for the treatment of depression in schizophrenia: a systematic review. Psychol. Med. 2003;33:589–599
  304. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder — reviewing the evidence and clinical recommendations. Prog. Neuropsychopharm. Biol. Psychiatry. 2008;32:1375–1385
  305. Wolff-Menzler C, Hasan A, Malchow B, et al. Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry. 2010;43:122–129
  306. Wolkowitz DM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psychiatry. 1991;148:714–726
  307. World Health Organization . W.H.O. Model List of Essential Medicines. 16th Edition. 2009;http://www.who.int/medicines/publication/essentialmedicines/en/index/html
  308. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 1991;17:325–351
  309. Wyatt RJ, Hunter I. Rationale for the study of early intervention. Schizophr. Res. 2001;51:69–76
  310. Wyatt RJ, Alexander RC, Egan MF, Kirch DG. Schizophrenia, just the facts. What do we know, how well do we know it?. Schizophr. Res. 1988;1:3–18
  311. Wykes T, Huddy V. Cognitive remediation for schizophrenia: it is even more complicated. Curr. Opin. Psychiatry. 2009;22:161–167
  312. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 2008;34:523–537
  313. Yang S-Y, Yang Y-HK, Chong M-Y, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin. Pharmacol. Ther. 2007;81:586–594
  314. Yoshikawa S, Hareyama N, Ikeda K, et al. Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. Eur. J. Pharmacol. 2009;606:102–108
  315. Yung AR, Killackey E, Hetrick SE, et al. The prevention of schizophrenia. Int. Rev. Psychiatry. 2007;19:633–646
  316. Zandi PP, Judy JT. The promise and reality of pharmacogenetics in psychiatry. Psychiatr. Clin. N. Am. 2010;33:181–224
  317. Zhang J, Xiong B, Zhen X, Zhang A. Dopamine D1 receptor ligands: where we are now and where are we going. Med. Res. Rev. 2009;29:272–294
  318. Zimmermann G, Favrod J, Trieu VH, et al. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr. Res. 2005;77:1–9
  319. Zink M, Englisch S, Meyer-Lindberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry. 2010;23:103–111
  320. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J. Clin. Psychiatry. 2009;70:562–571

PII: S0920-9964(10)01346-0

doi: 10.1016/j.schres.2010.05.025

Schizophrenia Research
Volume 122, Issue 1 , Pages 1-23 , September 2010

Article Tools

* Image Usage & Resolution